MELBOURNE, Australia and OXFORD, UK — October 5, 2026
Aravax announced that it will present topline Phase 2 results for PVX108, its investigational next-generation immunotherapy for peanut allergy, at major scientific meetings in the United States and Europe in November 2026. The company plans to communicate the results at the Annual Scientific Meeting of the American College of Allergy, Asthma and Clinical Immunology (ACAAI) in Phoenix, Arizona, from November 12–16 and at the European Academy of Allergy and Clinical Immunology (EAACI) Food Allergy Anaphylaxis and FAAM-EUROBAT-ISMA Congress in Utrecht, Netherlands, from November 19–21. PVX108 is being developed as a disease-modifying immunotherapy designed to retrain the immune system to tolerate peanut while minimizing the risk of treatment-induced acute allergic reactions associated with whole-allergen approaches. The candidate has received FDA Fast Track designation for the treatment of peanut allergy. The upcoming presentations will provide the first broad scientific communication of topline findings from Aravax’s international Phase 2 program and represent an important clinical development milestone for the company.
PVX108 Uses Peptide-Based Immunotherapy Approach
PVX108 is designed to promote immune tolerance to peanut through proprietary peptides that selectively retrain the immune system. Aravax is developing the candidate as a next-generation alternative to approaches that expose patients to whole allergens, which can carry a risk of acute allergic reactions during treatment. The company believes its peptide-based strategy may offer a differentiated safety and convenience profile while addressing the underlying immune response responsible for peanut allergy. PVX108 is administered intradermally in monthly doses, with the Phase 2 study designed to evaluate treatment over a 12-month period. According to Aravax, the therapy is intended to restore the body’s ability to tolerate peanut while minimizing the risk of significant treatment-induced reactions, including anaphylaxis. The company’s broader platform uses proprietary peptide technology to develop disease-modifying immunotherapies for food allergies, with additional food allergy indications planned for development.
Phase 2 Study Evaluates Children With Peanut Allergy
Aravax’s Phase 2 PVX108 study is a randomized, double-blind, placebo-controlled clinical trial conducted across sites in the United States and Australia. The study enrolled participants with peanut allergy into two cohorts, including a pilot safety adolescent cohort and a primary efficacy cohort consisting of children aged four to 11 years. Participants received monthly intradermal treatment over 12 months, allowing investigators to assess the candidate’s efficacy and safety in a pediatric population affected by peanut allergy. The study is registered as NCT05621317. Aravax has not yet disclosed the topline clinical results and plans to communicate the findings at the November scientific meetings. The release of these results will provide additional information on the clinical performance of PVX108 and help define the next stage of its development program. The company also said PVX108 is currently being studied in an extension arm of the international Phase 2 program
Advertisement
Aravax Advances Disease-Modifying Allergy Pipeline
The planned Phase 2 data presentations could provide an important update on Aravax’s strategy to develop safer, disease-modifying treatments for food allergy. Peanut allergy is a chronic condition in which accidental exposure can cause potentially serious allergic reactions, creating a need for therapies that can improve tolerance while reducing treatment-related risks. Aravax is positioning PVX108 around a mechanism intended to modify the immune response rather than simply manage allergic reactions after exposure. The company has attracted investment from international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper, supporting continued development of its platform. With FDA Fast Track designation already secured and Phase 2 topline results scheduled for communication in November, PVX108 is approaching a key decision point in its clinical development. The forthcoming data will be closely relevant to determining whether the peptide-based immunotherapy can demonstrate the desired balance of immune tolerance, efficacy and safety needed to advance toward later-stage development.
Source: VaxcytAravax, press release
